Technology

BPH Energy investee Cortical Dynamics advances brain monitoring technology

Go to Louis Allen author's page
By Louis Allen - 
BPH Energy investee Cortical Dynamics Globaluck BARM sales South Korea ASX BPH

BPH’s Cortical Dynamics is working with local distributor Globaluck to introduce the brain anaesthesia response monitoring device to the Korean market.

Copied

BPH Energy (ASX: BPH) has provided an update on its investee Cortical Dynamics, which continues to make steps towards advancing its brain anaesthesia response monitor (BARM) unit, which is described as an industry leading EEG (electrical activity) brain function monitor.

BARM is being developed by Cortical to better detect the effect of anaesthetic agents on brain activity to keep patients optimally anaesthetised.

The Perth-based medical device neurotechnology company considers its BARM unit to be “the world’s most reliable, flexible and objective medical brain monitoring technology capable of measuring both levels of unconsciousness and pain”.

Via trials and evaluation, BARM has been used in over 200 operations worldwide at several different hospitals with positive outcomes.

Cortical recently entered into a partnership with Austrian EEG experts ENCEVIS and AIT Austrian Institute of Technology in an effort to further refine its BARM technology.

With over 1,300 workers, the AIT is Austria’s largest research and technology organisation, with ENCEVIS making up one of its divisions and specialising in EEG.

AI prestigious grant

In June 2022, Cortical won a prestigious grant from Australia’s MTPConnect BioMedTech Horizons (BMTH) program. The grant will assist Cortical in developing AI and machine learning capacity for its BARM unit.

The BMTH program was set up to improve health outcomes for Australians, while strengthening the biomedical and medical technology sector, boosting employment and growing business, and is awarded to Australia’s best and brightest researchers.

In the past, the program has been successful in bringing cutting edge medical devices to market.

Cortical has made two appointments, a full-time project manager, but more notably a world class head of data analytics, bringing a focus on developing a greater understanding of sedation level monitoring systems using AI such as EEG, machine learning, statistical analysis, and anaesthesiology.

Application areas include optimal management of anaesthesia and sedatives in the operating room and the ICU.

Awaiting FDA approval

Cortical has commenced its Food and Drug Administration (FDA) 510K filing process for BARM in the US, with the help of Washington-based technical advisors MCRA.

The company is seeking FDA approval to commence sales of its BARM unit in the US.

Previously, BARM has already received Therapeutic Goods Administration (TGA) approval in Australia, Korean Ministry of Food and Drug Safety (MFDS) approval, and CE marking in the European Union.

US patent expands extensive portfolio

Throughout the year, Cortical continued to expand its IP portfolio in the US, developing an extensive patent portfolio protecting the BARM across several key brain monitoring markets.

Cortical has a competitive advantage with a strong patent position covered by five patent families and 36 granted patents.

The company already has protection across such key brain monitoring markets in the UK, Australia, New Zealand and Japan.

Cortical has also been awarded patents in France, Belgium, Germany, Netherlands, Switzerland, Italy, Ireland and the People’s Republic of China.

BPH, a diversified investment company, holds a 17.7% stake in the Cortical.